Piper Sandler downgraded Optinose (OPTN) to Neutral from Overweight with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN: